BioNxt Solutions Inc. (BNXT)

BRIEF

published on 12/19/2024 at 09:10, 2 days 4 hours ago

BioNxt Solutions Expands Patent Portfolio for Drug Delivery Innovations

Multiple Sclerosis BioNxt Solutions Sublingual Delivery Patent Expansion Drug Innovation
PRESS RELEASE

published on 12/19/2024 at 09:05, 2 days 4 hours ago

BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP
BioNxt Solutions Inc. expands its intellectual property portfolio with new international patents for sublingual delivery technologies targeting autoimmune neurodegenerative diseases. The company aims to bring patient-friendly therapies to individuals affected by these diseases

BioNxt Solutions Inc. Intellectual Property Patents Autoimmune Neurodegenerative Diseases Sublingual Delivery Technologies
BRIEF

published on 12/09/2024 at 09:10, 12 days 4 hours ago

BioNxt Solutions Advances BNT23001 for MS Treatment

Clinical Trials Drug Development Multiple Sclerosis BioNxt Solutions BNT23001
PRESS RELEASE

published on 12/09/2024 at 09:05, 12 days 4 hours ago

BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
BioNxt Solutions Inc. achieves key milestones in the development of BNT23001, a sublingual thin-film formulation of Cladribine for Multiple Sclerosis treatment, paving the way for clinical trials and regulatory submissions in 2025

Clinical Trials BioNxt Solutions Inc. Multiple Sclerosis Sublingual Thin-Film BNT23001
BRIEF

published on 12/02/2024 at 09:10, 19 days 4 hours ago

BioNxt Solutions Develops Sublingual Thin-Film for Semaglutide

Drug Delivery Innovation BioNxt Solutions Patient Compliance Sublingual Thin-Film Semaglutide
PRESS RELEASE

published on 12/02/2024 at 09:05, 19 days 4 hours ago

BioNxt Solutions Announces Development of Sublingual Thin-Film for Semaglutide
BioNxt Solutions Inc. introduces sublingual thin-film oral dissolvable film (ODF) for Semaglutide, enhancing patient experience and improving drug delivery

Innovation Healthcare BioNxt Solutions Inc. Drug Delivery Semaglutide
BRIEF

published on 11/25/2024 at 09:10, 26 days 4 hours ago

BioNxt Expands Sublingual Product Pipeline with Innovations

BioNxt Solutions Sublingual Technology Autoimmune Treatments Longevity Market Drug Delivery Systems
PRESS RELEASE

published on 11/25/2024 at 09:05, 26 days 4 hours ago

BioNxt Announces Enhanced Sublingual Product Development Pipeline with Innovative Solutions for Autoimmune Diseases and Longevity
BioNxt Solutions Inc. expands next-gen product pipeline targeting autoimmune diseases & longevity market. Innovative drug delivery systems show promise in major high-growth markets

BioNxt Solutions Inc. Next-Generation Technologies Autoimmune Diseases Longevity Market Drug Delivery Systems
BRIEF

published on 10/29/2024 at 08:10, 1 month 23 days ago

BioNxt Advances Patent Filings for Novel Drug Delivery

Multiple Sclerosis Patent Filings BioNxt Solutions Myasthenia Gravis Sublingual Drugs
PRESS RELEASE

published on 10/29/2024 at 08:05, 1 month 23 days ago

BioNxt Announces National Level Patent Filings for Sublingual Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
BioNxt Solutions Inc. initiates nationalization process for sublingual anticancer drug patents for autoimmune neurodegenerative diseases. Positive report from European Patent Office on patentability

BioNxt Solutions Inc. Patents Anticancer Drugs Sublingual Delivery Autoimmune Neurodegenerative Diseases

1 2 ... 6

Published on 12/21/2024 at 01:30, 12 hours 30 minutes ago

Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 12 hours 30 minutes ago

iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 13 hours 55 minutes ago

Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/21/2024 at 00:00, 14 hours ago

Amarc Announces Loan Extension
Published on 12/20/2024 at 23:30, 14 hours 30 minutes ago

Boron One Announces Extension to Early Warrant Exercise Incentive Program

View all ACCESSWIRE

Published on 12/21/2024 at 00:51, 13 hours 8 minutes ago

Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 13 hours 15 minutes ago

EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 18 hours 49 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 19 hours 4 minutes ago

CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/20/2024 at 18:00, 20 hours ago

ARYZTA AG Announces New Board Technology Committee

View all EQS

Published on 12/21/2024 at 12:17, 1 hour 42 minutes ago

AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 20 hours ago

Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 20 hours 5 minutes ago

Disclosure of trading in own shares from 16/12/2024 to 20/12/2024
Published on 12/20/2024 at 14:00, 1 day ago

Safran: Woodward Signs Agreement to Acquire Safran’ s Electromechanical Actuation Business based in North America
Published on 12/19/2024 at 18:30, 1 day 19 hours ago

Share capital decrease by way of treasury shares cancellation

View all LES ECHOS COMFI WIRE

News